Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa | Zendy

Adnan Alatoom | Zendy; Hashim Elsayed | Zendy; Karen Lawlor | Zendy; Laila AbdelWareth | Zendy; Rania M. El-Lababidi | Zendy; Lysettee Cardona | Zendy; Mohammad Mooty | Zendy; Maria-Fernanda Bonilla | Zendy; Ahmad Nusair | Zendy; Imran Mirza | Zendy

Open Access

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa

Author(s) -

Adnan Alatoom,

Hashim Elsayed,

Karen Lawlor,

Laila AbdelWareth,

Rania M. El-Lababidi,

Lysettee Cardona,

Mohammad Mooty,

Maria-Fernanda Bonilla,

Ahmad Nusair,

Imran Mirza

Publication year - 2017

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2017.06.007

Subject(s) - ceftazidime/avibactam , ceftazidime , microbiology and biotechnology , klebsiella pneumoniae , pseudomonas aeruginosa , etest , avibactam , tazobactam , biology , antimicrobial , medicine , escherichia coli , antibiotics , antibiotic resistance , bacteria , imipenem , biochemistry , genetics , gene

This study compared the activity of ceftolozane-tazobactam and ceftazidime-avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas aeruginosa, isolated from patients admitted to Cleveland Clinic Abu Dhabi, United Arab Emirates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research